Label Highlights CLARITIN Effectively Treats Indoor and Outdoor Allergies
KENILWORTH, N.J., Jan. 22 /PRNewswire-FirstCall/ -- Schering-Plough
(NYSE: SGP) today announced that the U.S. Food and Drug Administration has
approved additional labeling for CLARITIN(R) (loratadine), which clearly
tells consumers that the non-drowsy over-the-counter medication relieves
allergy symptoms caused by both indoor (also called perennial or
year-round) and outdoor (also called seasonal) allergies.
"Schering-Plough is pleased that the FDA has approved the change to the
CLARITIN label to help us to communicate to consumers that CLARITIN works
hard to relieve both indoor and outdoor allergies," said John E. O'Mullane,
BSc, PhD, Group Vice-President, Research and Development, Schering-Plough
Consumer Health Care.
Common indoor allergens include mold, dust mites, and pet dander, while
common outdoor allergens include grass, tree, and ragweed pollen. Though
they stem from different sources, indoor and outdoor allergies have the
same pathophysiology, meaning they affect the body in the same way.
Symptoms of both types of allergies include runny nose; sneezing; itchy,
watery eyes; and itching of the nose or throat.
"People often associate allergies with outdoor triggers like pollen and
grass, but many people's allergies are actually caused by things found in
their home, office, or school," said Marjorie Slankard, M.D., allergist and
clinical professor of medicine at the Columbia University College of
Physicians and Surgeons. "When choosing an allergy medication, it's
important to recognize that not all treatments are the same. Many patients
and providers prefer a non-drowsy antihistamine, such as CLARITIN, because
of its proven record in relieving symptoms of indoor and outdoor
allergies." CLARITIN is the only brand proven to keep allergy sufferers as
alert and focused as someone without allergies.* Allergy sufferers who are
unsure about which treatment option is right for them should talk to their
doctors.
CLARITIN is approved as effective against indoor (perennial) allergies
in 110 countries worldwide.
*Only brand clinically tested.
About CLARITIN
All CLARITIN brand products are available without a prescription,
including: CLARITIN Tablets, a once-daily full prescription strength, non-
drowsy formulation; CLARITIN RediTabs(R) Tablets, a novel once-daily
formulation in a quickly dissolving tablet for ages 6 and older;
CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the
decongestant pseudoephedrine now located behind the counter; CHILDREN'S
CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in
grape and fruit flavors; CHILDREN'S CLARITIN(R) Grape Chewables, a chewable
tablet for children ages 2 and older; and CLARITIN Hives Relief(TM)
tablets.
CLARITIN is the No. 1 physician-recommended and
pediatrician-recommended over-the-counter antihistamine brand for allergic
rhinitis. The CLARITIN Rx- to-OTC switch in 2002 was the largest switch
ever-and the first and only for a non-sedating antihistamine. For more
information on allergies and treatment, visit http://www.CLARITIN.com.
About Schering-Plough
Schering-Plough is an innovation-driven, science-centered global health
care company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and improve
lives around the world. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. In November 2007, Schering-Plough acquired Organon
BioSciences, with its Organon human health and Intervet animal health
businesses, marking a pivotal step in the company's ongoing transformation.
Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors,
patients, customers and other stakeholders served by its approximately
50,000 people around the world. The company is based in Kenilworth, N.J.,
and its Web site is http://www.schering-plough.com.
SOURCE Schering-Plough
 back to top
Related links:
http://www.schering-plough.com
http://www.CLARITIN.com/
http://www.prnewswire.com/comp/777050.html/
CONTACT:
Media, Julie Lux, +1-908-298-4774,
+1-908-216-0370 (cell); Investor, Robyn Brown, +1-908-298-7436,
both of Schering-Plough
|
